Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

CYCN

Cyclerion Therapeutics (CYCN)

Cyclerion Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CYCN
FechaHoraFuenteTítuloSímboloCompañía
07/05/202415:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCNCyclerion Therapeutics Inc
26/01/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYCNCyclerion Therapeutics Inc
11/12/202316:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CYCNCyclerion Therapeutics Inc
07/12/202315:05Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:CYCNCyclerion Therapeutics Inc
04/12/202316:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCNCyclerion Therapeutics Inc
04/12/202307:00GlobeNewswire Inc.Cyclerion Appoints Regina Graul, Ph.D., as PresidentNASDAQ:CYCNCyclerion Therapeutics Inc
30/11/202317:16GlobeNewswire Inc.Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorNASDAQ:CYCNCyclerion Therapeutics Inc
31/07/202306:00GlobeNewswire Inc.Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsNASDAQ:CYCNCyclerion Therapeutics Inc
20/06/202315:56Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:CYCNCyclerion Therapeutics Inc
09/06/202316:24Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:CYCNCyclerion Therapeutics Inc
01/06/202315:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYCNCyclerion Therapeutics Inc
01/06/202315:00GlobeNewswire Inc.Cyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CYCNCyclerion Therapeutics Inc
23/05/202315:00Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:CYCNCyclerion Therapeutics Inc
15/05/202312:00GlobeNewswire Inc.Cyclerion Announces Reverse Stock SplitNASDAQ:CYCNCyclerion Therapeutics Inc
12/05/202305:05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CYCNCyclerion Therapeutics Inc
11/05/202317:00GlobeNewswire Inc.Cyclerion Announces Definitive Agreement for Zagociguat and CY3018NASDAQ:CYCNCyclerion Therapeutics Inc
11/05/202317:00GlobeNewswire Inc.Cyclerion Announces Corporate Updates and Q1 2023 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
03/04/202306:30GlobeNewswire Inc.Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementNASDAQ:CYCNCyclerion Therapeutics Inc
27/03/202306:00GlobeNewswire Inc.Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial DiseasesNASDAQ:CYCNCyclerion Therapeutics Inc
22/03/202316:01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:CYCNCyclerion Therapeutics Inc
22/03/202315:40GlobeNewswire Inc.Cyclerion Reports Corporate Update and Full Year 2022 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
09/02/202309:02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYCNCyclerion Therapeutics Inc
13/01/202315:31Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CYCNCyclerion Therapeutics Inc
22/11/202206:00GlobeNewswire Inc.Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The CompanyNASDAQ:CYCNCyclerion Therapeutics Inc
21/10/202216:14Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:CYCNCyclerion Therapeutics Inc
06/10/202207:00GlobeNewswire Inc.Cyclerion Announces Mitochondrial Disease-Focused Corporate StrategyNASDAQ:CYCNCyclerion Therapeutics Inc
10/08/202215:46Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CYCNCyclerion Therapeutics Inc
09/08/202215:00GlobeNewswire Inc.Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
28/07/202206:00GlobeNewswire Inc.Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)NASDAQ:CYCNCyclerion Therapeutics Inc
26/07/202215:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYCNCyclerion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CYCN